trending Market Intelligence /marketintelligence/en/news-insights/trending/thM-9tjntseRkiMy1IkKIg2 content esgSubNav
In This List

UCB's psoriatic arthritis drug improved joint, skin symptoms in phase 2b trial

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


UCB's psoriatic arthritis drug improved joint, skin symptoms in phase 2b trial

UCB SA's psoriatic arthritis drug bimekizumab significantly improved joint and skin symptoms in a phase 2b trial.

Psoriatic arthritis is an inflammatory condition affecting the joints and skin.

The study met its primary goal with up to 46% of psoriatic arthritis patients who received the treatment seeing at least 50% improvement in joint symptoms after 12 weeks, compared with 7% of patients on placebo.

Among patients with skin lesions, 65% of those who received the drug experienced at least 90% skin clearance at week 12, compared with 7% who received placebo.

Bimekizumab has also demonstrated its efficacy in treating ankylosing spondylitis, a type of arthritis that mainly affects the spine. In a phase 2b study, 47% of patients receiving bimekizumab achieved at least 40% improvement in disease symptoms, compared to 13% receiving placebo after 12 weeks.